Discover
Visualize rapid, validated insights through real-world data.
Speaking with Canadian legislators about anonymization
By Replica staff Posted On: February 9th, 2022
Aetion’s comments to FDA on electronic health records and claims to support regulatory decisions
Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Understanding propensity score weighting methods
Oftentimes researchers want to compare two medications—an existing medication to a newly ...
PETs protect privacy and enable data use and sharing for good
By Khaled El Emam Posted On: January 28th, 2022
Hot off the presses: Replica’s acquisition by Aetion generates coverage
By Replica Analytics staff Posted On: January 24th, 2022
A 2021 round-up of 10 articles, media and events about Replica and its solutions
By Replica Analytics staff Posted On: January 13th, 2022
Why we acquired synthetic data pioneer Replica Analytics
The potential for real-world evidence (RWE) to improve patient lives and better protect ...
What I learned from former FDA leaders during Aetion’s RWE Summit
Aetion hosted our annual RWE Summit in New York last month, and I am still inspired by ...
8 Really Good Reasons to Work at Replica Analytics
By Replica Analytics staff Posted On: December 22nd, 2021 At Replica Analytics, we’re ...
Research spotlight: Using RWE to characterize prescription opioid dispensing patterns after surgical abortion
Over 800,000 abortions occur annually in the United States, the majority of which are ...
Predictions and resolutions for synthetic data
By Dr. Khaled El Emam Posted On: December 21st, 2021
Discover AI publishes 7 key use cases for synthetic data in the pharmaceutical industry
By Replica Analytics staff Posted On: December 16, 2021
Norwegian data protection authority strongly recommends synthetic data for software testing
By Dr. Khaled El Emam Posted On: December 2nd, 2021
Generating Synthetic Longitudinal Data
What industry can learn from RWE demonstration projects
As global regulatory and health technology assessment (HTA) bodies continue to iterate on ...
RWE guidance watch: EMA real world evidence guidance on registry-based studies
UPDATE: As of November 2021, EMA has now issued its final guideline on registry-based ...
New Gartner survey suggests synthetic data is the future of data sharing
By Dr. Khaled El Emam Posted On: November 9th, 2021
COVID-19 vaccine rollout shows real-world evidence was ready for the spotlight
Just 10 months since administration of the first COVID-19 vaccine dose, hundreds of ...
Synthetic Data Generation for Rare Disease Research
Join primary and real-world data to generate patient-relevant RWE across the product lifecycle: Q&A with Dr. Javier Jimenez of Syneos Health
Understanding how medical interventions impact patients has always been a top priority ...
Measuring Re-identification Risk for Synthetic and Anonymized Data
Ten Recommendations for Regulating Non-identifiable Data
There is considerable activity today in regulatory development and updates around the ...
Synthetic Data
ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology
This year at ICPE All Access, Aetion’s scientific research was represented across ...